EMA Authorised: Yargesa (miglustat) — Piramal Critical Care B.V.

View source ↗

Summary

The European Medicines Agency authorised Yargesa (miglustat) for Gaucher disease, with Piramal Critical Care B.V. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Yargesa (miglustat)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease. MAH: Piramal Critical Care B.V.. Decision date: 19/12/2025